Login Register Cart 0
Systematic Review Article

抗雄激素药物治疗强迫症：系统评价

卷 27, 期 40, 2020

页: [6825 - 6836] 页: 12

弟呕挨: 10.2174/0929867326666191209142209

价格: $65

摘要

目的：本研究旨在系统地研究与强迫症患者相比，安慰剂或常规护理相比，抗雄激素药物是否可以显着减轻强迫症（OCD）症状。 方法：截至2018年10月，使用相关关键字搜索PubMed，EMBASE，CENTRAL和国际临床试验注册平台（ICTRP）数据库。包括对包括强迫症患者在内的强迫症患者进行的所有随机且非随机性非随机研究，这些患者报告了其症状的变化。排除强迫性性欲研究。所需数据是由两名独立作者从所收文章的全文中提取的。发现一项随机试验和四项非随机试验。 结果：唯一的随机试验表明，与安慰剂相比，抗雄激素药物氟他胺可有效降低男性合并性Tourette综合征强迫症患者的强迫评分。四分之三的非随机试验表明，包括非那雄胺，醋酸环丙孕酮和曲普瑞林在内的不同抗雄激素类药物均可有效减轻OCD症状。唯一的研究未能显示出抗雄激素药的功效，该研究给OCD患者服用了氟他胺。尽管取得了积极的成果，但现有的研究基于推荐，评估，发展和评估工作组（GRADE）方法的等级提供了低质量的证据。 结论：可用的研究不足以精确回答我们的研究问题。仍然需要进一步的大型随机盲临床试验来评估抗雄激素在强迫症患者中的有效性。建议在设计研究和解释其结果时应考虑性别，合并症和耶鲁-布朗强迫症评分表（Y-BOCS）。

关键词: 强迫症，促黄体激素释放激素，神经固醇，脱氢表雄酮，N-甲基-D-天冬氨酸，Tourette综合征。

« Previous Next »
[1]
Goodman, W.K.; Grice, D.E.; Lapidus, K.A.; Coffey, B.J. Obsessive-compulsive disorder. Psychiatr. Clin. North Am., 2014, 37(3), 257-267.
[http://dx.doi.org/10.1016/j.psc.2014.06.004] [PMID: 25150561]
[2]
Lewin, A.B.; Park, J.M.; Jones, A.M.; Crawford, E.A.; De Nadai, A.S.; Menzel, J.; Arnold, E.B.; Murphy, T.K.; Storch, E.A. Family-based exposure and response prevention therapy for preschool-aged children with obsessive-compulsive disorder: a pilot randomized controlled trial. Behav. Res. Ther., 2014, 56, 30-38.
[http://dx.doi.org/10.1016/j.brat.2014.02.001] [PMID: 24657310]
[3]
Ruscio, A.M.; Stein, D.J.; Chiu, W.T.; Kessler, R.C. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol. Psychiatry, 2010, 15(1), 53-63.
[http://dx.doi.org/10.1038/mp.2008.94] [PMID: 18725912]
[4]
Pittenger, C.; Bloch, M.H.; Williams, K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology and treatment. Pharmacol. Ther., 2011, 132(3), 314-332.
[http://dx.doi.org/10.1016/j.pharmthera.2011.09.006] [PMID: 21963369]
[5]
Jahanbakhsh, S.P.; Manteghi, A.A.; Emami, S.A.; Mahyari, S.; Gholampour, B.; Mohammadpour, A.H.; Sahebkar, A. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: a randomized double-blind placebo-controlled trial. Complement. Ther. Med., 2016, 27, 25-29.
[http://dx.doi.org/10.1016/j.ctim.2016.03.018] [PMID: 27515872]
[6]
Hofmeijer-Sevink, M.K.; van Oppen, P.; van Megen, H.J.; Batelaan, N.M.; Cath, D.C.; van der Wee, N.J.A.; van den Hout, M.A.; van Balkom, A.J. Clinical relevance of comorbidity in obsessive compulsive disorder: the Netherlands OCD Association study. J. Affect. Disord., 2013, 150(3), 847-854.
[http://dx.doi.org/10.1016/j.jad.2013.03.014] [PMID: 23597943]
[7]
McDougle, C.J.; Goodman, W.K.; Leckman, J.F.; Price, L.H. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr. Clin. North Am., 1993, 16(4), 749-766.
[http://dx.doi.org/10.1016/S0193-953X(18)30148-5] [PMID: 8309811]
[8]
Reddy, D.S. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog. Brain Res; , 2010, 186, pp. 113-137.
[http://dx.doi.org/10.1016/b978-0-444-53630-3.00008-7] [PMID: 21094889]
[9]
Umathe, S.N.; Vaghasiya, J.M.; Jain, N.S.; Dixit, P.V. Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(7), 1161-1166.
[http://dx.doi.org/10.1016/j.pnpbp.2009.06.013] [PMID: 19549549]
[10]
Gaikwad, U.; Parle, M.; Kumar, A.; Gaikwad, D. Effect of ritanserin and leuprolide alone and combined on marble-burying behavior of mice. Acta Pol. Pharm., 2010, 67(5), 523-527.
[PMID: 20873421]
[11]
Uday, G.; Pravinkumar, B.; Manish, W.; Sudhir, U. LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur. J. Pharmacol., 2007, 563(1-3), 155-159.
[http://dx.doi.org/10.1016/j.ejphar.2007.02.016] [PMID: 17368614]
[12]
Lieberman, R. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology, 2001, 58(2)(Suppl. 1), 83-90.
[http://dx.doi.org/10.1016/S0090-4295(01)01247-X] [PMID: 11502457]
[13]
Anderson, J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int., 2003, 91(5), 455-461.
[http://dx.doi.org/10.1046/j.1464-410X.2003.04026.x] [PMID: 12603397]
[14]
Peterson, B.S.; Zhang, H.; Anderson, G.M.; Leckman, J.F. A double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J. Clin. Psychopharmacol., 1998, 18(4), 324-331.
[http://dx.doi.org/10.1097/00004714-199808000-00013] [PMID: 9690699]
[15]
Bini, V.; Frau, R.; Collu, M.; Paba, S.; Devoto, P.; Marrosu, F.; Bortolato, M. Blockade of 5-alpha reductase reduces compulsive behaviors in mice. Eur. Neuropsychopharmacol., 2009, 19, S296-S297.
[http://dx.doi.org/10.1016/S0924-977X(09)70439-0]
[16]
Kudryashov, N.V.; Kalinina, T.S.; Kasabov, K.A.; Shimshirt, A.A.; Volkova, A.V.; Zhmurenko, L.A.; Voronina, T.A. The role of neurosteroids metabolism in anticompulsive effect of pyrazole[c]pyridine derivative gizh-72. Eksperimental’naya i Klinicheskaya Farmakologiya, 2018, 81(12), 7-11.
[http://dx.doi.org/10.30906/0869-2092-2018-81-2-7-11]]
[17]
Eriksson, T. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin. Int. Clin. Psychopharmacol., 2007, 22(1), 57-61.
[http://dx.doi.org/10.1097/01.yic.0000224793.51900.cb]] [PMID: 17159461]
[18]
Kudryashov, N.V.; Kalinina, T.S.; Zhmurenko, L.A.; Voronina, T.A. Anticompulsive activity of a new pyrazolo[C]pyridine derivative GIZh-72 under conditions of unpredictable chronic mild stress. Bull. Exp. Biol. Med., 2016, 161(3), 377-380.
[http://dx.doi.org/10.1007/s10517-016-3418-y] [PMID: 27502699]
[19]
Casas, M.; Alvarez, E.; Duro, P.; Garcia-Ribera, C.; Udina, C.; Velat, A.; Abella, D.; Rodriguez-Espinosa, J.; Salva, P.; Jané, F. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr. Scand., 1986, 73(2), 221-222.
[http://dx.doi.org/10.1111/j.1600-0447.1986.tb10591.x] [PMID: 2939692]
[20]
Altemus, M.; Greenberg, B.D.; Keuler, D.; Jacobson, K.R.; Murphy, D.L. Open trial of flutamide for treatment of obsessive-compulsive disorder. J. Clin. Psychiatry, 1999, 60(7), 442-445.
[http://dx.doi.org/10.4088/JCP.v60n0704] [PMID: 10453797]
[21]
Muroni, A.; Paba, S.; Puligheddu, M.; Marrosu, F.; Bortolato, M. A preliminary study of finasteride in Tourette syndrome. Mov. Disord., 2011, 26(11), 2146-2147.
[http://dx.doi.org/10.1002/mds.23810] [PMID: 21618612]
[22]
Feldman, J.D.; Noshirvani, H.; Chu, C. Improvement in female patients with severe obsessions and/or compulsions treated with cyproterone acetate. Acta Psychiatr. Scand., 1988, 78(2), 254.
[http://dx.doi.org/10.1111/j.1600-0447.1988.tb06333.x] [PMID: 2975912]
[23]
Eriksson, T. Antiandrogenic treatment for obsessive-compulsive disorder. Am. J. Psychiatry, 2000, 157(3), 483-483.
[http://dx.doi.org/10.1176/appi.ajp.157.3.483] [PMID: 10698847]
[24]
Chouinard, G.; Bélanger, M.C.; Beauclair, L.; Sultan, S.; Murphy, B.E.P. Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1996, 20(6), 1067-1079.
[http://dx.doi.org/10.1016/0278-5846(96)00084-X] [PMID: 8888111]
[25]
Bortolato, M.; Muroni, A.; Marrosu, F. Treatment of Tourette’s syndrome with finasteride. Am. J. Psychiatry, 2007, 164(12), 1914-1915.
[http://dx.doi.org/10.1176/appi.ajp.2007.07060978] [PMID: 18056252]
[26]
Erbay, L.G.; Kartalci, S. Neurosteroid levels in patients with obsessive-compulsive disorder. Psychiatry Investig., 2015, 12(4), 538-544.
[http://dx.doi.org/10.4306/pi.2015.12.4.538] [PMID: 26508966]
[27]
Bigos, K.L.; Folan, M.M.; Jones, M.R.; Haas, G.L.; Kroboth, F.J.; Kroboth, P.D. Dysregulation of neurosteroids in obsessive compulsive disorder. J. Psychiatr. Res., 2009, 43(4), 442-445.
[http://dx.doi.org/10.1016/j.jpsychires.2008.04.007] [PMID: 18514738]
[28]
Lange, K.W.; Lange, K.M.; Hauser, J.; Tucha, L.; Tucha, O. Circadian rhythms in obsessive-compulsive disorder. J. Neural Transm. (Vienna), 2012, 119(10), 1077-1083.
[http://dx.doi.org/10.1007/s00702-012-0805-z]] [PMID: 22543530]
[29]
Bini, V.; Frau, R.; Collu, M.; Paba, S.; Devoto, P.; Marrosu, F.; Bortolato, M.P. 1. d. 017 Blockade of 5-alpha reductase reduces compulsive behaviors in mice. Eur. Neuropsychopharmacol., 2009, 19, S296-S297.
[http://dx.doi.org/10.1016/S0924-977X(09)70439-0]
[30]
de la Torre, B.; Norén, S.; Hedman, M.; Diczfalusy, E. Effect of cyproterone acetate (CPA) on gonadal and adrenal function in men. Contraception, 1979, 20(4), 377-396.
[http://dx.doi.org/10.1016/S0010-7824(79)80048-7] [PMID: 228907]
[31]
Geller, J.; Albert, J.; Nachtsheim, D.A.; Loza, D.; Geller, S. The effects of flutamide on total DHT and nuclear DHT levels in the human prostate. Prostate, 1981, 2(3), 309-314.
[http://dx.doi.org/10.1002/pros.2990020309] [PMID: 6170970]

Rights & Permissions Print Cite
Article Metrics
28
© 2024 Bentham Science Publishers | Privacy Policy